Integration of metabolomics in heart disease and diabetes research: Current achievements and future outlook

Bioanalysis

Volumn 3, Issue 19, 2011, Pages 2205-2222

  Dunn, Warwick B ^a   Goodacre, Royston ^a   Neyses, Ludwig ^a,b   Mamas, Mamas ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINO ACID; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CELECOXIB; DOXORUBICIN; FIBRIC ACID DERIVATIVE; HYDROLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN; METFORMIN; NUTRACEUTICAL; PHENOL DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; ROFECOXIB; ROSIGLITAZONE; ROSMARINUS OFFICINALIS EXTRACT; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; TRIENTINE; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ATHEROGENESIS; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL METABOLISM; CHINESE MEDICINE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIABETOGENESIS; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENOMICS; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HIGH THROUGHPUT SCREENING; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTESTINE FLORA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; METABOLITE; METABOLOMICS; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PROGNOSIS; PROTEOMICS; REVIEW; SINGLE DRUG DOSE; SYSTEMS BIOLOGY; WILSON DISEASE;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DIABETES MELLITUS; DRUG DISCOVERY; DRUG TOXICITY; GLUCOSE INTOLERANCE; HEART DISEASES; HUMANS; INSULIN RESISTANCE; MAMMALS; METABOLOMICS; RESEARCH DESIGN;

EID: 80053991414     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.223     Document Type: Review

References (115)

1. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem. Soc. Rev. 40(1), 387-426 (2011).
2. Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol. 16(9), 373-378 (1998). (Pubitemid 28410425)
3. Tweeddale H, Notley-Mcrobb L, Ferenci T. Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool ("metabolome") analysis. J. Bacteriol. 180(19), 5109-5116 (1998). (Pubitemid 28470937)
4. Fiehn O, Kopka J, Dormann P, Altmann T, Trethewey RN, Willmitzer L. Metabolite profiling for plant functional genomics. Nat. Biotechnol. 18(11), 1157-1161 (2000).
5. Roessner U, Wagner C, Kopka J, Trethewey RN, Willmitzer L. Simultaneous analysis of metabolites in potato tuber by gas chromatography-mass spectrometry. Plant J. 23(1), 131-142 (2000). (Pubitemid 30597788)
6. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29(11), 1181-1189 (1999).
7. Pauling L, Robinson AB, Teranish R, Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl Acad. Sci. USA 68(10), 2374 (1971).
8. Horning EC. Use of combined gas-liquid chromatography and mass Spectrometry for clinical problems. Clin. Chem. 14(8), 777 (1968).
9. Sellick CA, Knight D, Croxford AS et al. Evaluation of extraction processes for intracellular metabolite profiling of mammalian cells - matching extraction approaches to cell type and metabolite targets. Metabolomics 6, 427-438 (2010).
10. Kell DB, Oliver SG. Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. Bioessays 26(1), 99-105 (2004). (Pubitemid 38095354)
11. Brown M, Dunn WB, Ellis DI et al. A metabolome pipeline: from concept to data to knowledge. Metabolomics 1(1), 39-51 (2005). (Pubitemid 40973872)
12. Broadhurst DI, Kell DB. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2(4), 171-196 (2006). (Pubitemid 46099798)
13. Ellis DI, Goodacre R. Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy. Analyst 131(8), 875-885 (2006). (Pubitemid 44126542)
14. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom. Rev. 26(1), 51-78 (2007). (Pubitemid 46051813)
15. Want EJ, Wilson ID, Gika H et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat. Protoc. 5(6), 1005-1018 (2010).
16. Beckonert O, Coen M, Keun HC et al. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat. Protoc. 5(6), 1019-1032 (2010).
17. Beckonert O, Keun HC, Ebbels TMD et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2(11), 2692-2703 (2007).
18. Begley P, Francis-Mcintyre S, Dunn WB et al. Development and performance of a gas chromatography-time-of-flight mass spectrometry analysis for large-scale nontargeted metabolomic studies of human serum. Anal. Chem. 81(16), 7038-7046 (2009).
19. Zelena E, Dunn WB, Broadhurst D et al. Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal. Chem. 81(4), 1357-1364 (2009).
20. Dunn WB, Broadhurst D, Begley P et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 6(7), 1060-1083 (2011).
21. Gika HG, Macpherson E, Theodoridis GA, Wilson ID. Evaluation of the repeatability of ultra-performance liquid chromatography-TOF-MS for global metabolic profiling of human urine samples. J. Chromat. B 871(2), 299-305 (2008).
22. Van Der Kloet FM, Bobeldijk I, Verheij ER, Jellema RH. Analytical error reduction using single point calibration for accurate and precise metabolomic phenotyping. J. Proteome Res. 8(11), 5132-5141 (2009).
23. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics - a review in human disease diagnosis. Anal. Chim. Acta 659(1-2), 23-33 (2010).
24. Wishart DS, Knox C, Guo AC et al. HMDB. a knowledgebase for the human metabolome. Nucleic Acids Res. 37, D603-D610 (2009).
25. Dunn WB, Broadhurst DI, Deepak SM et al. Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2 oxoglutarate. Metabolomics 3, 413-426 (2007). (Pubitemid 350107675)
26. Nikolaidou T, Mamas M, Oceandy D, Neyses L. Biological action of a-ketoglutarate in the heart and kidney - a metabolite identified through a metabolomic search in patients with heart failure. Eur. J. Heart Failure (Suppl. 9), S268 (2010).
27. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004). (Pubitemid 38579764)
28. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care 21(7), 1138-1145 (1998). (Pubitemid 28368522)
29. Deaton C, Mamas MA, Rutter MK et al. Glucose and insulin abnormalities in patients with heart failure. Eur. J. Cardiovasc. Nursing 10(2), 75-87 (2011).
30. Brun E, Nelson RG, Bennett PH et al. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care 23(8), 1119-1123 (2000). (Pubitemid 30616799)
31. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl. 2), S14-S21 (2001). (Pubitemid 32844108)
32. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J. Am. Col. Cardiol. 47(5), 921-929 (2006).
33. Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker and pathway discovery. J. Am. Col. Cardiol. 52(2), 117-123 (2008). (Pubitemid 351885452)
34. Barderas MG, Laborde CM, Posada M et al. Metabolomic profiling for identification of novel potential biomarkers in cardiovascular diseases. J. Biomed. Biotechnol. 790132 (2011).
35. El Azzouzi H, De Windt LJ. Heart spotting. Basic Res. Cardiol. 103(3), 228-231 (2008).
36. Goonewardena SN, Prevette LE, Desai AA. Metabolomics and atherosclerosis. Curr. Atheroscl. Rep. 12(4), 267-272 (2010).
37. Samuel JL, Schaub MC, Zaugg M, Mamas M, Dunn WB, Swynghedauw B. Genomics in cardiac metabolism. Cardiovasc. Res. 79(2), 218-227 (2008). (Pubitemid 351951605)
38. Waterman CL, Kian-Kai C, Griffin JL. Metabolomic strategies to study lipotoxicity in cardiovascular disease. Biochim. Biophys. Acta 1801(3), 230-234 (2010).
39. Wheelock CE, Wheelock AM, Kawashima S et al. Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol. Biosyst. 5(6), 588-602 (2009).
40. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharm. Ther. 69(3), 89-95 (2001).
41. Mamas M, Dunn WB, Neyses L, Goodacre R. The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch. Toxicol. 85(1), 5-17 (2011).
42. Wang TJ, Larson MG, Vasan RS et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17(4), 448-U483 (2011).
43. Krebs M, Krssak M, Bernroider E et al. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes 51(3), 599-605 (2002). (Pubitemid 34760165)
44. Patti ME, Kahn CR. The insulin receptor - a critical link in glucose homeostasis and insulin action. J. Basic Clin. Physiol. Pharmacol. 9(2-4), 89-109 (1998). (Pubitemid 29143595)
45. Oreŝic M, Simell S, Sysi-Aho M et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to Type 1 diabetes. J. Exp. Med. 205(13), 2975-2984 (2008).
46. Shaham O, Wei R, Wang TJ et al. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol. Syst. Biol. 4, 214 (2008).
47. Suhre K, Meisinger C, Doering A et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One 5(11), e13953 (2010).
48. Rhee EP, Cheng S, Larson MG et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J. Clin. Invest. 121(4), 1402-1411 (2011).
49. Bougneres P, Valleron A-J. Causes of early-onset Type 1 diabetes: toward data-driven environmental approaches. J. Exp. Med. 205(13), 2953-2957 (2008).
50. Knip M, Virtanen SM, Akerblom HK. Infant feeding and the risk of Type 1 diabetes. Am. J. Clin. Nutr. 91(5), 1506S-1513S (2010).
51. Zhao XJ, Fritsche J, Wang JS et al. Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 6(3), 362-374 (2010).
52. Lucio M, Fekete A, Weigert C et al. Insulin sensitivity is reflected by characteristic metabolic fingerprints - a fourier transform mass spectrometric non-targeted metabolomics approach. PLoS One 5(10), e13317 (2010).
53. Sabatine MS, Liu E, Morrow DA et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112(25), 3868-3875 (2005). (Pubitemid 43739484)
54. Barba I, De Leon G, Martin E et al. Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn. Res. Med. 60(1), 27-32 (2008) (Pubitemid 351956606)
55. Lin HL, Zhang J, Gao P. Silent myocardial ischemia is associated with altered plasma phospholipids. J. Clin. Lab. Anal. 23(1), 45-50 (2009).
56. Brindle JT, Antti H, Holmes E et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H 1-NMR-based metabonomics. Nat. Med. 8(12), 1439-1444 (2002). (Pubitemid 36019430)
57. Kirschenlohr HL, Griffin JL, Clarke SC et al. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat. Med. 12(6), 705-710 (2006). (Pubitemid 43865242)
58. Lewis GD, Wei R, Liu E et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J. Clin. Invest. 118(10), 3503-3512 (2008).
59. Mamas M, Dunn W, Broadhurst D et al. Serum metabolomics identifies novel signature metabolites in very early cardiac ischaemia: first in human study. Circulation 120(18), S892-S892 (2009).
60. Chen X, Liu LA, Palacios G et al. Plasma metabolomics reveals biomarkers of the atherosclerosis. J. Sep. Sci. 33(17-18), 2776-2783 (2010).
61. Ciborowski M, Martin-Ventura JL, Meilhac O et al. Metabolites secreted by human atherothrombotic aneurysms revealed through a metabolomic approach. J. Proteome Res. 10(3), 1374-1382 (2011).
62. Wang ZN, Tang WHW, Cho L, Brennan DM, Hazen SL. Targeted metabolomic evaluation of arginine methylation and cardiovascular risks potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler. Thromb. Vasc. Biol. 29(9), 1383-1391 (2009).
63. Leo GC, Darrow AL. NMR-based metabolomics of urine for the atherosclerotic mouse model using apolipoprotein-E deficient mice. Magn. Res. Chem. 47, S20-S25 (2009).
64. Mayr M, Chung YL, Mayr U et al. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler. Thromb. Vasc. Biol. 25(10), 2135-2142 (2005). (Pubitemid 41416312)
65. Mercer JR, Cheng KK, Figg N et al. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ. Res. 107(8), U1159 (2010).
66. Zhang FX, Jia ZH, Gao P et al. Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Talanta 79(3), 836-844 (2009).
67. Zha WB, A JY, Wang GJ et al. Metabonomic characterization of early atherosclerosis in hamsters with induced cholesterol. Biomarkers 14(6), 372-380 (2009).
68. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444(7122), 1027-1031 (2006). (Pubitemid 46018515)
69. Dumas ME, Barton RH, Toye A et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl Acad. Sci. USA 103(33), 12511-12516 (2006). (Pubitemid 44267289)
70. Wang ZN, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472(7341), 57-82 (2011).
71. Cheng KK, Benson GM, Grimsditch DC, Reid DG, Connor SC, Griffin JL. Metabolomic study of the LDL receptor null mouse fed a high-fat diet reveals profound perturbations in choline metabolism that are shared with ApoE null mice. Physiol. Genomics 41(3), 224-231 (2010).
72. Teul J, Ruperez FJ, Garcia A et al. Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. J. Proteome Res. 8(12), 5580-5589 (2009).
73. Alexander D, Lombardi R, Rodriguez G, Mitchell MM, Marian AJ. Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. Eur. J. Clin. Invest. 41(5), 527-538 (2011).
74. Nikolaidou T, Mamas M, Dunn W, Oceandy D, Neyses L. Biological action of a-ketoglutarate in the heart and kidney - a metabolite identified through a metabolomic search in patients with heart failure. Eur. J. Heart Failure (Suppl. 9), S268 (2010).
75. Mervaala E, Biala A, Merasto S et al. Metabolomics in angiotensin II-induced cardiac hypertrophy. Hypertension 55(2), 508-515 (2010).
76. Kao HJ, Cheng CF, Chen YH et al. ENU mutagenesis identifies mice with cardiac fibrosis and hepatic steatosis caused by a mutation in the mitochondrial trifunctional protein β-subunit. Human Mol. Genetics 15(24), 3569-3577 (2006).
77. De Souza AI, Cardin S, Wait R et al. Proteomic and metabolomic analysis of atrial profibrillatory remodelling in congestive heart failure. J. Mol. Cell. Cardiol. 49(5), 851-863 (2010).
78. Mayr M, Chung YL, Mayr U et al. Loss of PKC d alters cardiac metabolism. Am. J. Physiol. 287(2), H937-H945 (2004). (Pubitemid 38955333)
79. Mayr M, Liem D, Zhang J et al. Proteomic and metabolomic analysis of cardioprotection: Interplay between protein kinase C e and d in regulating glucose metabolism of murine hearts. J. Mol. Cell. Cardiol. 46(2), 268-277 (2009).
80. Turer AT, Stevens RD, Bain JR et al. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation 119(13), U1736-U1788 (2009).
81. Shah SH, Hauser ER, Bain JR et al. High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol. Syst. Biol. 5, 258 (2009).
82. Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes research moving from information to knowledge. Diabetes 58(11), 2429-2443 (2009).
83. Griffin JL, Nicholls AW. Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders. Pharmacogenomics 7(7), 1095-1107 (2006). (Pubitemid 44649115)
84. Griffin JL, Vidal-Puig A. Current challenges in metabolomics for diabetes research: a vital functional genomic tool or just a ploy for gaining funding? Physiol. Genomics 34(1), 1-5 (2008).
85. Newgard CB, Attie AD. Getting biological about the genetics of diabetes. Nat. Med. 16(4), 388-391 (2010).
86. Atherton HJ, Bailey NJ, Zhang W et al. A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR a null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol. Genomics 27(2), 178-186 (2006). (Pubitemid 46702031)
87. Connor SC, Hansen MK, Corner A, Smith RF, Ryan TE. Integration of metabolomics and transcriptomics data to aid biomarker discovery in Type 2 diabetes. Mol. Biosyst. 6(5), 909-921 (2010).
88. Tsutsui H, Maeda T, Toyo'oka T et al. Practical analytical approach for the identification of biomarker candidates in prediabetic state based upon metabonomic study by ultraperformance liquid chromatography coupled to electrospray ionization time-of-flight mass spectrometry. J. Proteome Res. 9(8), 3912-3922 (2010).
89. Zhang SC, Gowda GN, Asiago V, Shanaiah N, Barbas C, Raftery D. Correlative and quantitative H 1 NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats. Anal. Biochem. 383(1), 76-84 (2008).
90. Lanza IR, Zhang SC, Ward LE, Karakelides H, Raftery D, Nair KS. Quantitative metabolomics by H 1-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PloS One 5(5), e10538 (2010).
91. Spegel P, Malmgren SI, Sharoyko VV, Newsholme P, Koeck T, Mulder H. Metabolomic analyses reveal profound differences in glycolytic and tricarboxylic acid cycle metabolism in glucose-responsive and -unresponsive clonal β-cell lines. Biochem. J. 435, 277-284 (2011).
92. Tai ES, Tan MLS, Stevens RD et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia 53(4), 757-767 (2010).
93. Zisman A, Peroni OD, Abel ED et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med. 6(8), 924-928 (2000). (Pubitemid 30644753)
94. Koonen DPY, Sung MMY, Kao CKC et al. Alterations in skeletal muscle fatty acid handling predisposes middle-aged mice to diet-induced insulin resistance. Diabetes 59(6), 1366-1375 (2010).
95. Koves TR, Ussher JR, Noland RC et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7(1), 45-56 (2008).
96. Kuhl J, Moritz T, Wagner H et al. Metabolomics as a tool to evaluate exercise-induced improvements in insulin sensitivity. Metabolomics 4(3), 273-282 (2008).
97. Zhao XJ, Peter A, Fritsche J et al. Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am. J. Physiol. 296(2), E384-E393 (2009).
98. Lin S, Yang Z, Liu H, Tang L, Cai Z. Beyond glucose: metabolic shifts in responses to the effects of the oral glucose tolerance test and the high-fructose diet in rats. Mol. Biosyst. 7(5), 1537-1548 (2011).
99. Janis MT, Laaksonen R, Oresic M. Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs. Expert Opin. Drug Metab. Toxicol. 4(6), 665-680 (2008). (Pubitemid 352003192)
100. Kaddurah-Daouk R, Baillie RA, Zhu HJ et al. Lipidomic analysis of variation in response to simvastatin in the cholesterol and pharmacogenetics study. Metabolomics 6(2), 191-201 (2010).
101. Li N, Liu J-Y, Timofeyev V et al. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches. J. Mol. Cell. Cardiol. 47(6), 835-845 (2009).
102. Andreadou I, Papaefthimiou M, Zira A et al. Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein. NMR Biomed. 22(6), 585-592 (2009).
103. Lv YH, Liu XR, Yan SK et al. Metabolomic study of myocardial ischemia and intervention effects of Compound Danshen Tablets in rats using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J. Pharm. Biomed. Anal. 52(1), 129-135 (2010).
104. Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 10(2), 111-126 (2011).
105. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343(21), 1520-1528 (2000).
106. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352(11), 1092-1102 (2005). (Pubitemid 40365350)
107. Lu J, Gong D, Choong SY et al. Copper(II)- selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments. Diabetologia 53(6), 1217-1226 (2010).
108. Aitken JF, Loomes KM, Scott DW et al. Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice. Diabetes 59(1), 161-171 (2010).
109. Godzien J, Ciborowski M, Angulo S et al. Metabolomic approach with LC-QTOF to study the effect of a nutraceutical treatment on urine of diabetic rats. J. Proteome Res. 10(2), 837-844 (2011).
110. Gu Y, Zhang YF, Shi XZ et al. Effect of traditional Chinese medicine berberine on Type 2 diabetes based on comprehensive metabonomics. Talanta 81(3), 766-772 (2010).
111. Huo TG, Cai S, Lu XM, Sha Y, Yu MY, Li FM. Metabonomic study of biochemical changes in the serum of Type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J. Pharm. Biomed. Anal. 49(4), 976-982 (2009).
112. Wang MY, Chen LJ, Clark GO et al. Leptin therapy in insulin-deficient Type I diabetes. Proc. Natl Acad. Sci. USA 107(11), 4813-4819 (2010).
113. Zhang HY, Saha J, Byun J et al. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am. J. Physiol. 295(4), F1071-F1081 (2008).
114. Van Doorn M, Vogels J, Tas A et al. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. Br. J. Clin. Pharmacol. 63(5), 562-574 (2007). (Pubitemid 46632578)
115. Bao YQ, Zhao T, Wang XY et al. Metabonomic variations in the drug-treated Type 2 diabetes mellitus patients and healthy volunteers. J. Proteome Res. 8(4), 1623-1630 (2009).